nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—ABCB1—hematologic cancer	0.0865	1	CbGaD
Maprotiline—ORM1—Imatinib—hematologic cancer	0.0473	0.0955	CbGbCtD
Maprotiline—CYP1A2—Anagrelide—hematologic cancer	0.0383	0.0772	CbGbCtD
Maprotiline—ABCB1—Lenalidomide—hematologic cancer	0.0232	0.0468	CbGbCtD
Maprotiline—CYP2D6—Lomustine—hematologic cancer	0.0203	0.041	CbGbCtD
Maprotiline—CYP1A2—Carmustine—hematologic cancer	0.0201	0.0405	CbGbCtD
Maprotiline—CYP2D6—Idarubicin—hematologic cancer	0.0181	0.0365	CbGbCtD
Maprotiline—CYP1A2—Methoxsalen—hematologic cancer	0.0171	0.0345	CbGbCtD
Maprotiline—CYP1A2—Bortezomib—hematologic cancer	0.0163	0.0328	CbGbCtD
Maprotiline—CYP1A2—Daunorubicin—hematologic cancer	0.0156	0.0314	CbGbCtD
Maprotiline—CYP2D6—Hydroxyurea—hematologic cancer	0.0154	0.0311	CbGbCtD
Maprotiline—CYP1A2—Alitretinoin—hematologic cancer	0.0152	0.0307	CbGbCtD
Maprotiline—CYP1A2—Thalidomide—hematologic cancer	0.0142	0.0286	CbGbCtD
Maprotiline—ABCB1—Daunorubicin—hematologic cancer	0.0136	0.0274	CbGbCtD
Maprotiline—CYP2D6—Bortezomib—hematologic cancer	0.0134	0.027	CbGbCtD
Maprotiline—ABCB1—Alitretinoin—hematologic cancer	0.0133	0.0269	CbGbCtD
Maprotiline—CYP1A2—Dacarbazine—hematologic cancer	0.0122	0.0246	CbGbCtD
Maprotiline—CYP1A2—Imatinib—hematologic cancer	0.0119	0.024	CbGbCtD
Maprotiline—ABCB1—Imatinib—hematologic cancer	0.0104	0.021	CbGbCtD
Maprotiline—CYP2D6—Imatinib—hematologic cancer	0.00982	0.0198	CbGbCtD
Maprotiline—CYP1A2—Dasatinib—hematologic cancer	0.00957	0.0193	CbGbCtD
Maprotiline—ABCB1—Nilotinib—hematologic cancer	0.00947	0.0191	CbGbCtD
Maprotiline—ABCB1—Vinorelbine—hematologic cancer	0.00939	0.0189	CbGbCtD
Maprotiline—CYP2D6—Nilotinib—hematologic cancer	0.00892	0.018	CbGbCtD
Maprotiline—CYP2D6—Vinorelbine—hematologic cancer	0.00885	0.0178	CbGbCtD
Maprotiline—ABCB1—Dasatinib—hematologic cancer	0.00837	0.0169	CbGbCtD
Maprotiline—ABCB1—Mitoxantrone—hematologic cancer	0.00827	0.0167	CbGbCtD
Maprotiline—ABCB1—Betamethasone—hematologic cancer	0.00737	0.0149	CbGbCtD
Maprotiline—ABCB1—Gemcitabine—hematologic cancer	0.0073	0.0147	CbGbCtD
Maprotiline—ABCB1—Prednisolone—hematologic cancer	0.00727	0.0147	CbGbCtD
Maprotiline—ABCB1—Prednisone—hematologic cancer	0.00687	0.0138	CbGbCtD
Maprotiline—ABCB1—Irinotecan—hematologic cancer	0.00651	0.0131	CbGbCtD
Maprotiline—CYP1A2—Etoposide—hematologic cancer	0.00596	0.012	CbGbCtD
Maprotiline—ABCB1—Vinblastine—hematologic cancer	0.00579	0.0117	CbGbCtD
Maprotiline—ABCB1—Vincristine—hematologic cancer	0.00569	0.0115	CbGbCtD
Maprotiline—CYP2D6—Vinblastine—hematologic cancer	0.00545	0.011	CbGbCtD
Maprotiline—ABCB1—Cisplatin—hematologic cancer	0.00531	0.0107	CbGbCtD
Maprotiline—ABCB1—Etoposide—hematologic cancer	0.00521	0.0105	CbGbCtD
Maprotiline—ABCB1—Dexamethasone—hematologic cancer	0.00429	0.00864	CbGbCtD
Maprotiline—CYP2D6—Dexamethasone—hematologic cancer	0.00404	0.00814	CbGbCtD
Maprotiline—ABCB1—Doxorubicin—hematologic cancer	0.00356	0.00717	CbGbCtD
Maprotiline—ABCB1—Methotrexate—hematologic cancer	0.00344	0.00694	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—hematologic cancer	0.00335	0.00675	CbGbCtD
Maprotiline—ORM1—hematopoietic system—hematologic cancer	0.00103	0.0535	CbGeAlD
Maprotiline—CHRM4—testis—hematologic cancer	0.000984	0.0509	CbGeAlD
Maprotiline—SLC6A3—hematopoietic system—hematologic cancer	0.000961	0.0497	CbGeAlD
Maprotiline—HTR7—hematopoietic system—hematologic cancer	0.000747	0.0387	CbGeAlD
Maprotiline—ORM1—blood—hematologic cancer	0.000684	0.0354	CbGeAlD
Maprotiline—ORM1—bone marrow—hematologic cancer	0.000662	0.0343	CbGeAlD
Maprotiline—ORM1—lung—hematologic cancer	0.0006	0.0311	CbGeAlD
Maprotiline—CYP1A2—hematopoietic system—hematologic cancer	0.000596	0.0308	CbGeAlD
Maprotiline—SLC6A2—gonad—hematologic cancer	0.000589	0.0305	CbGeAlD
Maprotiline—HTR7—gonad—hematologic cancer	0.000568	0.0294	CbGeAlD
Maprotiline—SLC6A3—lung—hematologic cancer	0.000558	0.0289	CbGeAlD
Maprotiline—HRH1—hematopoietic system—hematologic cancer	0.000558	0.0289	CbGeAlD
Maprotiline—SLC6A3—testis—hematologic cancer	0.000526	0.0272	CbGeAlD
Maprotiline—CHRM1—lung—hematologic cancer	0.000509	0.0264	CbGeAlD
Maprotiline—HTR7—blood—hematologic cancer	0.000495	0.0256	CbGeAlD
Maprotiline—HTR2A—hematopoietic system—hematologic cancer	0.000466	0.0241	CbGeAlD
Maprotiline—SLC6A2—lung—hematologic cancer	0.00045	0.0233	CbGeAlD
Maprotiline—HTR7—lung—hematologic cancer	0.000434	0.0225	CbGeAlD
Maprotiline—CHRM3—testis—hematologic cancer	0.00043	0.0223	CbGeAlD
Maprotiline—SLC6A2—testis—hematologic cancer	0.000425	0.022	CbGeAlD
Maprotiline—CYP2D6—hematopoietic system—hematologic cancer	0.000424	0.022	CbGeAlD
Maprotiline—ORM1—lymph node—hematologic cancer	0.00041	0.0212	CbGeAlD
Maprotiline—DRD2—lung—hematologic cancer	0.00041	0.0212	CbGeAlD
Maprotiline—HTR7—testis—hematologic cancer	0.000409	0.0212	CbGeAlD
Maprotiline—CYP1A2—blood—hematologic cancer	0.000395	0.0204	CbGeAlD
Maprotiline—DRD2—testis—hematologic cancer	0.000387	0.02	CbGeAlD
Maprotiline—HTR2A—gonad—hematologic cancer	0.000354	0.0183	CbGeAlD
Maprotiline—CYP1A2—lung—hematologic cancer	0.000346	0.0179	CbGeAlD
Maprotiline—HRH1—lung—hematologic cancer	0.000324	0.0168	CbGeAlD
Maprotiline—HTR2A—blood—hematologic cancer	0.000309	0.016	CbGeAlD
Maprotiline—SLC6A2—lymph node—hematologic cancer	0.000308	0.0159	CbGeAlD
Maprotiline—HRH1—testis—hematologic cancer	0.000306	0.0158	CbGeAlD
Maprotiline—ABCB1—hematopoietic system—hematologic cancer	0.000305	0.0158	CbGeAlD
Maprotiline—CYP2D6—blood—hematologic cancer	0.000281	0.0146	CbGeAlD
Maprotiline—HTR2A—lung—hematologic cancer	0.000271	0.014	CbGeAlD
Maprotiline—HTR2A—testis—hematologic cancer	0.000255	0.0132	CbGeAlD
Maprotiline—Sertraline—ABCB1—hematologic cancer	0.000251	0.304	CrCbGaD
Maprotiline—CYP2D6—testis—hematologic cancer	0.000233	0.012	CbGeAlD
Maprotiline—ABCB1—gonad—hematologic cancer	0.000232	0.012	CbGeAlD
Maprotiline—HRH1—lymph node—hematologic cancer	0.000222	0.0115	CbGeAlD
Maprotiline—ABCB1—blood—hematologic cancer	0.000202	0.0105	CbGeAlD
Maprotiline—ABCB1—bone marrow—hematologic cancer	0.000196	0.0101	CbGeAlD
Maprotiline—ABCB1—lung—hematologic cancer	0.000177	0.00918	CbGeAlD
Maprotiline—ABCB1—testis—hematologic cancer	0.000167	0.00866	CbGeAlD
Maprotiline—Desipramine—SLC22A1—hematologic cancer	0.000157	0.189	CrCbGaD
Maprotiline—Protriptyline—ABCB1—hematologic cancer	0.000144	0.175	CrCbGaD
Maprotiline—Imipramine—SLC22A1—hematologic cancer	0.000133	0.161	CrCbGaD
Maprotiline—ABCB1—lymph node—hematologic cancer	0.000121	0.00628	CbGeAlD
Maprotiline—Nortriptyline—ALB—hematologic cancer	5.8e-05	0.0701	CrCbGaD
Maprotiline—Desipramine—ABCB1—hematologic cancer	4.55e-05	0.0551	CrCbGaD
Maprotiline—Imipramine—ABCB1—hematologic cancer	3.86e-05	0.0467	CrCbGaD
Maprotiline—Erythema multiforme—Epirubicin—hematologic cancer	3.65e-05	0.000124	CcSEcCtD
Maprotiline—Anxiety—Prednisone—hematologic cancer	3.65e-05	0.000124	CcSEcCtD
Maprotiline—Alopecia—Methotrexate—hematologic cancer	3.65e-05	0.000124	CcSEcCtD
Maprotiline—Vomiting—Gemcitabine—hematologic cancer	3.64e-05	0.000124	CcSEcCtD
Maprotiline—Insomnia—Dexamethasone—hematologic cancer	3.64e-05	0.000124	CcSEcCtD
Maprotiline—Insomnia—Betamethasone—hematologic cancer	3.64e-05	0.000124	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.63e-05	0.000123	CcSEcCtD
Maprotiline—Paraesthesia—Dexamethasone—hematologic cancer	3.62e-05	0.000123	CcSEcCtD
Maprotiline—Paraesthesia—Betamethasone—hematologic cancer	3.62e-05	0.000123	CcSEcCtD
Maprotiline—Rash—Gemcitabine—hematologic cancer	3.61e-05	0.000123	CcSEcCtD
Maprotiline—Dermatitis—Gemcitabine—hematologic cancer	3.61e-05	0.000123	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—hematologic cancer	3.61e-05	0.000123	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—hematologic cancer	3.6e-05	0.000122	CcSEcCtD
Maprotiline—Malnutrition—Methotrexate—hematologic cancer	3.59e-05	0.000122	CcSEcCtD
Maprotiline—Headache—Gemcitabine—hematologic cancer	3.59e-05	0.000122	CcSEcCtD
Maprotiline—Nausea—Vincristine—hematologic cancer	3.59e-05	0.000122	CcSEcCtD
Maprotiline—Flushing—Epirubicin—hematologic cancer	3.58e-05	0.000122	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—hematologic cancer	3.58e-05	0.000122	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—hematologic cancer	3.57e-05	0.000121	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—hematologic cancer	3.55e-05	0.000121	CcSEcCtD
Maprotiline—Dyspepsia—Dexamethasone—hematologic cancer	3.55e-05	0.00012	CcSEcCtD
Maprotiline—Dyspepsia—Betamethasone—hematologic cancer	3.55e-05	0.00012	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—hematologic cancer	3.53e-05	0.00012	CcSEcCtD
Maprotiline—Urticaria—Triamcinolone—hematologic cancer	3.53e-05	0.00012	CcSEcCtD
Maprotiline—Dysgeusia—Methotrexate—hematologic cancer	3.52e-05	0.000119	CcSEcCtD
Maprotiline—Asthenia—Etoposide—hematologic cancer	3.51e-05	0.000119	CcSEcCtD
Maprotiline—Body temperature increased—Triamcinolone—hematologic cancer	3.51e-05	0.000119	CcSEcCtD
Maprotiline—Oedema—Prednisone—hematologic cancer	3.51e-05	0.000119	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—hematologic cancer	3.5e-05	0.000119	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—hematologic cancer	3.5e-05	0.000119	CcSEcCtD
Maprotiline—Nausea—Mitoxantrone—hematologic cancer	3.49e-05	0.000119	CcSEcCtD
Maprotiline—Nausea—Irinotecan—hematologic cancer	3.49e-05	0.000119	CcSEcCtD
Maprotiline—Infection—Prednisone—hematologic cancer	3.48e-05	0.000118	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—hematologic cancer	3.48e-05	0.000118	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.48e-05	0.000118	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.48e-05	0.000118	CcSEcCtD
Maprotiline—Fatigue—Betamethasone—hematologic cancer	3.47e-05	0.000118	CcSEcCtD
Maprotiline—Fatigue—Dexamethasone—hematologic cancer	3.47e-05	0.000118	CcSEcCtD
Maprotiline—Pruritus—Etoposide—hematologic cancer	3.46e-05	0.000118	CcSEcCtD
Maprotiline—Shock—Prednisone—hematologic cancer	3.45e-05	0.000117	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—hematologic cancer	3.45e-05	0.000117	CcSEcCtD
Maprotiline—Nervous system disorder—Prednisone—hematologic cancer	3.44e-05	0.000117	CcSEcCtD
Maprotiline—Tachycardia—Prednisone—hematologic cancer	3.42e-05	0.000116	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—hematologic cancer	3.41e-05	0.000116	CcSEcCtD
Maprotiline—Skin disorder—Prednisone—hematologic cancer	3.41e-05	0.000116	CcSEcCtD
Maprotiline—Nausea—Gemcitabine—hematologic cancer	3.4e-05	0.000116	CcSEcCtD
Maprotiline—Vomiting—Cisplatin—hematologic cancer	3.4e-05	0.000115	CcSEcCtD
Maprotiline—Hyperhidrosis—Prednisone—hematologic cancer	3.39e-05	0.000115	CcSEcCtD
Maprotiline—Vision blurred—Methotrexate—hematologic cancer	3.38e-05	0.000115	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—hematologic cancer	3.38e-05	0.000115	CcSEcCtD
Maprotiline—Rash—Cisplatin—hematologic cancer	3.37e-05	0.000114	CcSEcCtD
Maprotiline—Dermatitis—Cisplatin—hematologic cancer	3.36e-05	0.000114	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—hematologic cancer	3.36e-05	0.000114	CcSEcCtD
Maprotiline—Diarrhoea—Etoposide—hematologic cancer	3.35e-05	0.000114	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—hematologic cancer	3.34e-05	0.000113	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—hematologic cancer	3.33e-05	0.000113	CcSEcCtD
Maprotiline—Feeling abnormal—Dexamethasone—hematologic cancer	3.32e-05	0.000113	CcSEcCtD
Maprotiline—Feeling abnormal—Betamethasone—hematologic cancer	3.32e-05	0.000113	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—hematologic cancer	3.32e-05	0.000113	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—hematologic cancer	3.32e-05	0.000113	CcSEcCtD
Maprotiline—Tension—Epirubicin—hematologic cancer	3.3e-05	0.000112	CcSEcCtD
Maprotiline—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.29e-05	0.000112	CcSEcCtD
Maprotiline—Gastrointestinal pain—Betamethasone—hematologic cancer	3.29e-05	0.000112	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—hematologic cancer	3.29e-05	0.000112	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—hematologic cancer	3.26e-05	0.000111	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—hematologic cancer	3.24e-05	0.00011	CcSEcCtD
Maprotiline—Dizziness—Etoposide—hematologic cancer	3.24e-05	0.00011	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—hematologic cancer	3.22e-05	0.000109	CcSEcCtD
Maprotiline—Leukopenia—Methotrexate—hematologic cancer	3.21e-05	0.000109	CcSEcCtD
Maprotiline—Urticaria—Dexamethasone—hematologic cancer	3.2e-05	0.000109	CcSEcCtD
Maprotiline—Urticaria—Betamethasone—hematologic cancer	3.2e-05	0.000109	CcSEcCtD
Maprotiline—Dizziness—Prednisolone—hematologic cancer	3.19e-05	0.000108	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—hematologic cancer	3.19e-05	0.000108	CcSEcCtD
Maprotiline—Asthenia—Triamcinolone—hematologic cancer	3.18e-05	0.000108	CcSEcCtD
Maprotiline—Body temperature increased—Dexamethasone—hematologic cancer	3.18e-05	0.000108	CcSEcCtD
Maprotiline—Abdominal pain—Betamethasone—hematologic cancer	3.18e-05	0.000108	CcSEcCtD
Maprotiline—Abdominal pain—Dexamethasone—hematologic cancer	3.18e-05	0.000108	CcSEcCtD
Maprotiline—Body temperature increased—Betamethasone—hematologic cancer	3.18e-05	0.000108	CcSEcCtD
Maprotiline—Nausea—Cisplatin—hematologic cancer	3.17e-05	0.000108	CcSEcCtD
Maprotiline—Insomnia—Prednisone—hematologic cancer	3.17e-05	0.000108	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—hematologic cancer	3.17e-05	0.000108	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—hematologic cancer	3.16e-05	0.000107	CcSEcCtD
Maprotiline—Paraesthesia—Prednisone—hematologic cancer	3.15e-05	0.000107	CcSEcCtD
Maprotiline—Pruritus—Triamcinolone—hematologic cancer	3.14e-05	0.000107	CcSEcCtD
Maprotiline—Convulsion—Methotrexate—hematologic cancer	3.11e-05	0.000106	CcSEcCtD
Maprotiline—Vomiting—Etoposide—hematologic cancer	3.11e-05	0.000106	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—hematologic cancer	3.11e-05	0.000106	CcSEcCtD
Maprotiline—Agitation—Epirubicin—hematologic cancer	3.09e-05	0.000105	CcSEcCtD
Maprotiline—Dyspepsia—Prednisone—hematologic cancer	3.09e-05	0.000105	CcSEcCtD
Maprotiline—Rash—Etoposide—hematologic cancer	3.09e-05	0.000105	CcSEcCtD
Maprotiline—Dermatitis—Etoposide—hematologic cancer	3.08e-05	0.000105	CcSEcCtD
Maprotiline—Headache—Etoposide—hematologic cancer	3.07e-05	0.000104	CcSEcCtD
Maprotiline—Tension—Doxorubicin—hematologic cancer	3.05e-05	0.000104	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—hematologic cancer	3.05e-05	0.000103	CcSEcCtD
Maprotiline—Rash—Prednisolone—hematologic cancer	3.04e-05	0.000103	CcSEcCtD
Maprotiline—Dermatitis—Prednisolone—hematologic cancer	3.04e-05	0.000103	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.04e-05	0.000103	CcSEcCtD
Maprotiline—Fatigue—Prednisone—hematologic cancer	3.02e-05	0.000103	CcSEcCtD
Maprotiline—Headache—Prednisolone—hematologic cancer	3.02e-05	0.000103	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—hematologic cancer	3.02e-05	0.000103	CcSEcCtD
Maprotiline—Syncope—Epirubicin—hematologic cancer	3.01e-05	0.000102	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—hematologic cancer	3.01e-05	0.000102	CcSEcCtD
Maprotiline—Constipation—Prednisone—hematologic cancer	3e-05	0.000102	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—hematologic cancer	2.97e-05	0.000101	CcSEcCtD
Maprotiline—Confusional state—Methotrexate—hematologic cancer	2.96e-05	0.0001	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—hematologic cancer	2.95e-05	0.0001	CcSEcCtD
Maprotiline—Dizziness—Triamcinolone—hematologic cancer	2.94e-05	9.97e-05	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—hematologic cancer	2.93e-05	9.95e-05	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—hematologic cancer	2.91e-05	9.89e-05	CcSEcCtD
Maprotiline—Infection—Methotrexate—hematologic cancer	2.91e-05	9.89e-05	CcSEcCtD
Maprotiline—Nausea—Etoposide—hematologic cancer	2.91e-05	9.87e-05	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—hematologic cancer	2.9e-05	9.86e-05	CcSEcCtD
Maprotiline—Feeling abnormal—Prednisone—hematologic cancer	2.89e-05	9.82e-05	CcSEcCtD
Maprotiline—Asthenia—Dexamethasone—hematologic cancer	2.89e-05	9.81e-05	CcSEcCtD
Maprotiline—Asthenia—Betamethasone—hematologic cancer	2.89e-05	9.81e-05	CcSEcCtD
Maprotiline—Nervous system disorder—Methotrexate—hematologic cancer	2.87e-05	9.76e-05	CcSEcCtD
Maprotiline—Thrombocytopenia—Methotrexate—hematologic cancer	2.87e-05	9.75e-05	CcSEcCtD
Maprotiline—Gastrointestinal pain—Prednisone—hematologic cancer	2.87e-05	9.74e-05	CcSEcCtD
Maprotiline—Nausea—Prednisolone—hematologic cancer	2.87e-05	9.74e-05	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—hematologic cancer	2.86e-05	9.71e-05	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—hematologic cancer	2.85e-05	9.68e-05	CcSEcCtD
Maprotiline—Pruritus—Betamethasone—hematologic cancer	2.85e-05	9.68e-05	CcSEcCtD
Maprotiline—Pruritus—Dexamethasone—hematologic cancer	2.85e-05	9.68e-05	CcSEcCtD
Maprotiline—Skin disorder—Methotrexate—hematologic cancer	2.85e-05	9.67e-05	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.84e-05	9.65e-05	CcSEcCtD
Maprotiline—Hyperhidrosis—Methotrexate—hematologic cancer	2.83e-05	9.62e-05	CcSEcCtD
Maprotiline—Vomiting—Triamcinolone—hematologic cancer	2.82e-05	9.58e-05	CcSEcCtD
Maprotiline—Rash—Triamcinolone—hematologic cancer	2.8e-05	9.5e-05	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—hematologic cancer	2.8e-05	9.5e-05	CcSEcCtD
Maprotiline—Dermatitis—Triamcinolone—hematologic cancer	2.8e-05	9.5e-05	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—hematologic cancer	2.79e-05	9.47e-05	CcSEcCtD
Maprotiline—Urticaria—Prednisone—hematologic cancer	2.79e-05	9.46e-05	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—hematologic cancer	2.78e-05	9.45e-05	CcSEcCtD
Maprotiline—Headache—Triamcinolone—hematologic cancer	2.78e-05	9.44e-05	CcSEcCtD
Maprotiline—Abdominal pain—Prednisone—hematologic cancer	2.77e-05	9.42e-05	CcSEcCtD
Maprotiline—Body temperature increased—Prednisone—hematologic cancer	2.77e-05	9.42e-05	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—hematologic cancer	2.77e-05	9.39e-05	CcSEcCtD
Maprotiline—Diarrhoea—Betamethasone—hematologic cancer	2.76e-05	9.36e-05	CcSEcCtD
Maprotiline—Diarrhoea—Dexamethasone—hematologic cancer	2.76e-05	9.36e-05	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—hematologic cancer	2.75e-05	9.33e-05	CcSEcCtD
Maprotiline—Oedema—Epirubicin—hematologic cancer	2.74e-05	9.32e-05	CcSEcCtD
Maprotiline—Hypotension—Methotrexate—hematologic cancer	2.74e-05	9.3e-05	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—hematologic cancer	2.73e-05	9.28e-05	CcSEcCtD
Maprotiline—Infection—Epirubicin—hematologic cancer	2.73e-05	9.26e-05	CcSEcCtD
Maprotiline—Shock—Epirubicin—hematologic cancer	2.7e-05	9.17e-05	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—hematologic cancer	2.69e-05	9.15e-05	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—hematologic cancer	2.69e-05	9.14e-05	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—hematologic cancer	2.69e-05	9.12e-05	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—hematologic cancer	2.68e-05	9.12e-05	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—hematologic cancer	2.68e-05	9.09e-05	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—hematologic cancer	2.66e-05	9.05e-05	CcSEcCtD
Maprotiline—Dizziness—Dexamethasone—hematologic cancer	2.66e-05	9.05e-05	CcSEcCtD
Maprotiline—Dizziness—Betamethasone—hematologic cancer	2.66e-05	9.05e-05	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—hematologic cancer	2.65e-05	9.01e-05	CcSEcCtD
Maprotiline—Insomnia—Methotrexate—hematologic cancer	2.65e-05	9e-05	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—hematologic cancer	2.64e-05	8.96e-05	CcSEcCtD
Maprotiline—Nausea—Triamcinolone—hematologic cancer	2.64e-05	8.95e-05	CcSEcCtD
Maprotiline—Paraesthesia—Methotrexate—hematologic cancer	2.63e-05	8.94e-05	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.63e-05	8.93e-05	CcSEcCtD
Maprotiline—Somnolence—Methotrexate—hematologic cancer	2.61e-05	8.85e-05	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—hematologic cancer	2.59e-05	8.79e-05	CcSEcCtD
Maprotiline—Dyspepsia—Methotrexate—hematologic cancer	2.58e-05	8.76e-05	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—hematologic cancer	2.56e-05	8.71e-05	CcSEcCtD
Maprotiline—Vomiting—Dexamethasone—hematologic cancer	2.56e-05	8.7e-05	CcSEcCtD
Maprotiline—Vomiting—Betamethasone—hematologic cancer	2.56e-05	8.7e-05	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—hematologic cancer	2.56e-05	8.69e-05	CcSEcCtD
Maprotiline—Rash—Dexamethasone—hematologic cancer	2.54e-05	8.62e-05	CcSEcCtD
Maprotiline—Rash—Betamethasone—hematologic cancer	2.54e-05	8.62e-05	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—hematologic cancer	2.54e-05	8.62e-05	CcSEcCtD
Maprotiline—Dermatitis—Dexamethasone—hematologic cancer	2.54e-05	8.62e-05	CcSEcCtD
Maprotiline—Dermatitis—Betamethasone—hematologic cancer	2.54e-05	8.62e-05	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.53e-05	8.59e-05	CcSEcCtD
Maprotiline—Fatigue—Methotrexate—hematologic cancer	2.53e-05	8.58e-05	CcSEcCtD
Maprotiline—Headache—Betamethasone—hematologic cancer	2.52e-05	8.57e-05	CcSEcCtD
Maprotiline—Headache—Dexamethasone—hematologic cancer	2.52e-05	8.57e-05	CcSEcCtD
Maprotiline—Infection—Doxorubicin—hematologic cancer	2.52e-05	8.56e-05	CcSEcCtD
Maprotiline—Asthenia—Prednisone—hematologic cancer	2.52e-05	8.55e-05	CcSEcCtD
Maprotiline—Shock—Doxorubicin—hematologic cancer	2.5e-05	8.48e-05	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—hematologic cancer	2.49e-05	8.45e-05	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—hematologic cancer	2.49e-05	8.44e-05	CcSEcCtD
Maprotiline—Pruritus—Prednisone—hematologic cancer	2.48e-05	8.43e-05	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—hematologic cancer	2.48e-05	8.43e-05	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—hematologic cancer	2.48e-05	8.41e-05	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—hematologic cancer	2.47e-05	8.37e-05	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—hematologic cancer	2.46e-05	8.37e-05	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—hematologic cancer	2.45e-05	8.33e-05	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—hematologic cancer	2.44e-05	8.28e-05	CcSEcCtD
Maprotiline—Feeling abnormal—Methotrexate—hematologic cancer	2.42e-05	8.2e-05	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—hematologic cancer	2.41e-05	8.2e-05	CcSEcCtD
Maprotiline—Diarrhoea—Prednisone—hematologic cancer	2.4e-05	8.15e-05	CcSEcCtD
Maprotiline—Gastrointestinal pain—Methotrexate—hematologic cancer	2.4e-05	8.14e-05	CcSEcCtD
Maprotiline—Nausea—Dexamethasone—hematologic cancer	2.39e-05	8.12e-05	CcSEcCtD
Maprotiline—Nausea—Betamethasone—hematologic cancer	2.39e-05	8.12e-05	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—hematologic cancer	2.37e-05	8.05e-05	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.37e-05	8.04e-05	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—hematologic cancer	2.36e-05	8.03e-05	CcSEcCtD
Maprotiline—Constipation—Epirubicin—hematologic cancer	2.35e-05	7.97e-05	CcSEcCtD
Maprotiline—Urticaria—Methotrexate—hematologic cancer	2.33e-05	7.91e-05	CcSEcCtD
Maprotiline—Dizziness—Prednisone—hematologic cancer	2.32e-05	7.88e-05	CcSEcCtD
Maprotiline—Body temperature increased—Methotrexate—hematologic cancer	2.32e-05	7.87e-05	CcSEcCtD
Maprotiline—Abdominal pain—Methotrexate—hematologic cancer	2.32e-05	7.87e-05	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—hematologic cancer	2.3e-05	7.8e-05	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—hematologic cancer	2.28e-05	7.74e-05	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—hematologic cancer	2.26e-05	7.68e-05	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—hematologic cancer	2.26e-05	7.66e-05	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—hematologic cancer	2.24e-05	7.62e-05	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—hematologic cancer	2.23e-05	7.59e-05	CcSEcCtD
Maprotiline—Vomiting—Prednisone—hematologic cancer	2.23e-05	7.57e-05	CcSEcCtD
Maprotiline—Rash—Prednisone—hematologic cancer	2.21e-05	7.51e-05	CcSEcCtD
Maprotiline—Dermatitis—Prednisone—hematologic cancer	2.21e-05	7.5e-05	CcSEcCtD
Maprotiline—Headache—Prednisone—hematologic cancer	2.2e-05	7.46e-05	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.19e-05	7.44e-05	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—hematologic cancer	2.19e-05	7.43e-05	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—hematologic cancer	2.18e-05	7.4e-05	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—hematologic cancer	2.17e-05	7.37e-05	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—hematologic cancer	2.17e-05	7.36e-05	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—hematologic cancer	2.17e-05	7.36e-05	CcSEcCtD
Maprotiline—Asthenia—Methotrexate—hematologic cancer	2.1e-05	7.14e-05	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—hematologic cancer	2.09e-05	7.1e-05	CcSEcCtD
Maprotiline—Nausea—Prednisone—hematologic cancer	2.08e-05	7.08e-05	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.08e-05	7.05e-05	CcSEcCtD
Maprotiline—Pruritus—Methotrexate—hematologic cancer	2.07e-05	7.04e-05	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—hematologic cancer	2.02e-05	6.85e-05	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—hematologic cancer	2.01e-05	6.81e-05	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—hematologic cancer	2.01e-05	6.81e-05	CcSEcCtD
Maprotiline—Diarrhoea—Methotrexate—hematologic cancer	2.01e-05	6.81e-05	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—hematologic cancer	1.97e-05	6.68e-05	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—hematologic cancer	1.94e-05	6.59e-05	CcSEcCtD
Maprotiline—Dizziness—Methotrexate—hematologic cancer	1.94e-05	6.58e-05	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—hematologic cancer	1.88e-05	6.37e-05	CcSEcCtD
Maprotiline—Vomiting—Methotrexate—hematologic cancer	1.86e-05	6.33e-05	CcSEcCtD
Maprotiline—Rash—Methotrexate—hematologic cancer	1.85e-05	6.28e-05	CcSEcCtD
Maprotiline—Dermatitis—Methotrexate—hematologic cancer	1.85e-05	6.27e-05	CcSEcCtD
Maprotiline—Headache—Methotrexate—hematologic cancer	1.84e-05	6.24e-05	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—hematologic cancer	1.82e-05	6.18e-05	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—hematologic cancer	1.81e-05	6.16e-05	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—hematologic cancer	1.8e-05	6.1e-05	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—hematologic cancer	1.74e-05	5.92e-05	CcSEcCtD
Maprotiline—Nausea—Methotrexate—hematologic cancer	1.74e-05	5.91e-05	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—hematologic cancer	1.74e-05	5.9e-05	CcSEcCtD
Maprotiline—Rash—Epirubicin—hematologic cancer	1.73e-05	5.87e-05	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—hematologic cancer	1.73e-05	5.87e-05	CcSEcCtD
Maprotiline—Headache—Epirubicin—hematologic cancer	1.72e-05	5.84e-05	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—hematologic cancer	1.68e-05	5.7e-05	CcSEcCtD
Maprotiline—Nausea—Epirubicin—hematologic cancer	1.63e-05	5.53e-05	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—hematologic cancer	1.61e-05	5.48e-05	CcSEcCtD
Maprotiline—Rash—Doxorubicin—hematologic cancer	1.6e-05	5.44e-05	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—hematologic cancer	1.6e-05	5.43e-05	CcSEcCtD
Maprotiline—Headache—Doxorubicin—hematologic cancer	1.59e-05	5.4e-05	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—hematologic cancer	1.51e-05	5.12e-05	CcSEcCtD
Maprotiline—HTR2C—Signaling Pathways—JUN—hematologic cancer	2.82e-06	2.74e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MDM2—hematologic cancer	2.82e-06	2.74e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.81e-06	2.73e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MDM2—hematologic cancer	2.81e-06	2.73e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—hematologic cancer	2.81e-06	2.73e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	2.8e-06	2.72e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MDM2—hematologic cancer	2.8e-06	2.72e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MDM2—hematologic cancer	2.79e-06	2.71e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MTOR—hematologic cancer	2.78e-06	2.71e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	2.78e-06	2.71e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—hematologic cancer	2.78e-06	2.7e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	2.78e-06	2.7e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	2.77e-06	2.69e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MDM2—hematologic cancer	2.77e-06	2.69e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	2.74e-06	2.66e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MTOR—hematologic cancer	2.74e-06	2.66e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MTOR—hematologic cancer	2.73e-06	2.66e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	2.73e-06	2.66e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	2.73e-06	2.66e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—hematologic cancer	2.73e-06	2.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MTOR—hematologic cancer	2.73e-06	2.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.73e-06	2.65e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MTOR—hematologic cancer	2.72e-06	2.64e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	2.72e-06	2.64e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.69e-06	2.61e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	2.69e-06	2.61e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MTOR—hematologic cancer	2.69e-06	2.61e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—hematologic cancer	2.68e-06	2.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—EP300—hematologic cancer	2.68e-06	2.6e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	2.67e-06	2.59e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	2.66e-06	2.59e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—hematologic cancer	2.66e-06	2.58e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	2.62e-06	2.54e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	2.61e-06	2.54e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—hematologic cancer	2.61e-06	2.54e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—hematologic cancer	2.61e-06	2.54e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	2.6e-06	2.53e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EP300—hematologic cancer	2.6e-06	2.53e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	2.59e-06	2.52e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	2.59e-06	2.51e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	2.57e-06	2.5e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	2.57e-06	2.5e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—hematologic cancer	2.57e-06	2.5e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	2.57e-06	2.49e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—hematologic cancer	2.56e-06	2.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.56e-06	2.49e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—hematologic cancer	2.56e-06	2.49e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.56e-06	2.48e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	2.55e-06	2.48e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—hematologic cancer	2.54e-06	2.47e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.54e-06	2.47e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	2.54e-06	2.47e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.54e-06	2.46e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.53e-06	2.46e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.53e-06	2.46e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	2.52e-06	2.45e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—hematologic cancer	2.52e-06	2.45e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	2.52e-06	2.45e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.52e-06	2.45e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.52e-06	2.45e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—hematologic cancer	2.51e-06	2.44e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—hematologic cancer	2.51e-06	2.44e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—hematologic cancer	2.51e-06	2.44e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.5e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—hematologic cancer	2.5e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—hematologic cancer	2.5e-06	2.43e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—hematologic cancer	2.5e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	2.5e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—hematologic cancer	2.5e-06	2.42e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CREBBP—hematologic cancer	2.49e-06	2.42e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.49e-06	2.42e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—hematologic cancer	2.49e-06	2.42e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—JUN—hematologic cancer	2.49e-06	2.42e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—hematologic cancer	2.48e-06	2.41e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—hematologic cancer	2.47e-06	2.4e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—hematologic cancer	2.47e-06	2.4e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	2.46e-06	2.39e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.46e-06	2.39e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—hematologic cancer	2.46e-06	2.39e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.45e-06	2.38e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.45e-06	2.38e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.45e-06	2.38e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—JUN—hematologic cancer	2.44e-06	2.37e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—hematologic cancer	2.44e-06	2.37e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.44e-06	2.37e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—JUN—hematologic cancer	2.43e-06	2.37e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.43e-06	2.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—hematologic cancer	2.43e-06	2.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—JUN—hematologic cancer	2.43e-06	2.36e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—hematologic cancer	2.41e-06	2.35e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.41e-06	2.34e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—hematologic cancer	2.41e-06	2.34e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.41e-06	2.34e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—JUN—hematologic cancer	2.4e-06	2.34e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—hematologic cancer	2.38e-06	2.32e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.37e-06	2.31e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	2.37e-06	2.3e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.37e-06	2.3e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.37e-06	2.3e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—hematologic cancer	2.36e-06	2.3e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	2.36e-06	2.29e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	2.36e-06	2.29e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—hematologic cancer	2.36e-06	2.29e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2.35e-06	2.29e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	2.35e-06	2.29e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.35e-06	2.28e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2.35e-06	2.28e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—hematologic cancer	2.35e-06	2.28e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ALB—hematologic cancer	2.33e-06	2.27e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	2.33e-06	2.26e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.33e-06	2.26e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—hematologic cancer	2.32e-06	2.26e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.32e-06	2.25e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK8—hematologic cancer	2.31e-06	2.25e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—hematologic cancer	2.31e-06	2.25e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.31e-06	2.24e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—hematologic cancer	2.3e-06	2.24e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	2.3e-06	2.24e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	2.3e-06	2.23e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	2.3e-06	2.23e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EP300—hematologic cancer	2.29e-06	2.23e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	2.29e-06	2.23e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—hematologic cancer	2.28e-06	2.22e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—hematologic cancer	2.28e-06	2.22e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	2.27e-06	2.21e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	2.27e-06	2.2e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—hematologic cancer	2.27e-06	2.2e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	2.26e-06	2.2e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EP300—hematologic cancer	2.26e-06	2.19e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EP300—hematologic cancer	2.25e-06	2.19e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.25e-06	2.19e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EP300—hematologic cancer	2.25e-06	2.18e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EP300—hematologic cancer	2.24e-06	2.18e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.23e-06	2.17e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SRC—hematologic cancer	2.23e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.23e-06	2.17e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EP300—hematologic cancer	2.22e-06	2.15e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ALB—hematologic cancer	2.2e-06	2.14e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SRC—hematologic cancer	2.2e-06	2.13e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SRC—hematologic cancer	2.19e-06	2.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SRC—hematologic cancer	2.18e-06	2.12e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—hematologic cancer	2.18e-06	2.12e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—hematologic cancer	2.18e-06	2.12e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SRC—hematologic cancer	2.18e-06	2.12e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—hematologic cancer	2.17e-06	2.11e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SRC—hematologic cancer	2.16e-06	2.1e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—hematologic cancer	2.15e-06	2.09e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.15e-06	2.09e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NRAS—hematologic cancer	2.15e-06	2.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.14e-06	2.08e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—hematologic cancer	2.13e-06	2.07e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—hematologic cancer	2.13e-06	2.07e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	2.13e-06	2.07e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	2.12e-06	2.06e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.12e-06	2.06e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—hematologic cancer	2.11e-06	2.05e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	2.05e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	2.05e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—hematologic cancer	2.11e-06	2.05e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.1e-06	2.05e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NRAS—hematologic cancer	2.1e-06	2.04e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	2.1e-06	2.04e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—hematologic cancer	2.1e-06	2.04e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NRAS—hematologic cancer	2.09e-06	2.04e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.09e-06	2.03e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—hematologic cancer	2.09e-06	2.03e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—hematologic cancer	2.08e-06	2.02e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NRAS—hematologic cancer	2.07e-06	2.02e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.06e-06	2e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK3—hematologic cancer	2.06e-06	2e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.02e-06	1.97e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK3—hematologic cancer	2.02e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—hematologic cancer	2.01e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	2.01e-06	1.96e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	2.01e-06	1.95e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—hematologic cancer	2e-06	1.94e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.99e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.99e-06	1.94e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	1.99e-06	1.93e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—hematologic cancer	1.98e-06	1.92e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—hematologic cancer	1.97e-06	1.91e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—hematologic cancer	1.96e-06	1.91e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	1.96e-06	1.91e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.96e-06	1.9e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.96e-06	1.9e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.95e-06	1.9e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—hematologic cancer	1.95e-06	1.9e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	1.95e-06	1.89e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.94e-06	1.89e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—hematologic cancer	1.93e-06	1.88e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—hematologic cancer	1.93e-06	1.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	1.93e-06	1.87e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.92e-06	1.87e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.89e-06	1.83e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALB—hematologic cancer	1.86e-06	1.81e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.86e-06	1.81e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.85e-06	1.8e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—hematologic cancer	1.82e-06	1.77e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	1.76e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	1.76e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—hematologic cancer	1.8e-06	1.75e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—hematologic cancer	1.79e-06	1.73e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.78e-06	1.73e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—hematologic cancer	1.78e-06	1.73e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.78e-06	1.73e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.7e-06	1.66e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—EP300—hematologic cancer	1.7e-06	1.65e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.7e-06	1.65e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—hematologic cancer	1.68e-06	1.63e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.62e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.62e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.66e-06	1.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	1.66e-06	1.61e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.65e-06	1.6e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—hematologic cancer	1.64e-06	1.6e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	1.64e-06	1.59e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—hematologic cancer	1.62e-06	1.57e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.62e-06	1.57e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—hematologic cancer	1.61e-06	1.57e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.61e-06	1.56e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—hematologic cancer	1.6e-06	1.56e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—EP300—hematologic cancer	1.6e-06	1.56e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—hematologic cancer	1.59e-06	1.54e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.57e-06	1.53e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.57e-06	1.53e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.55e-06	1.5e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.54e-06	1.5e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.54e-06	1.49e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—hematologic cancer	1.53e-06	1.49e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—hematologic cancer	1.52e-06	1.47e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—hematologic cancer	1.5e-06	1.46e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.44e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—hematologic cancer	1.48e-06	1.43e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.47e-06	1.43e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.47e-06	1.43e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.45e-06	1.41e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—hematologic cancer	1.42e-06	1.38e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.39e-06	1.35e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	1.33e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	1.32e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	1.32e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—EP300—hematologic cancer	1.36e-06	1.32e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.35e-06	1.31e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.34e-06	1.3e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.26e-06	1.22e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.18e-06	1.15e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—hematologic cancer	1.03e-06	9.98e-06	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1e-06	9.75e-06	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—hematologic cancer	9.67e-07	9.4e-06	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—hematologic cancer	8.2e-07	7.96e-06	CbGpPWpGaD
